740MO Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 34; p. S507
Main Authors Mirza, M.R., Sharma, S., Herrstedt, J., Shahin, M.S., Cibula, D., Fleming, E., Raspagliesi, F., Buscema, J., Hanker, L.C., Coleman, R.L., Boere, I.A., Schneider, K., Gilbert, L., Slomovitz, B.M., Teneriello, M.G., Powell, M.A., Ghosh, S., Stevens, S., Ring, K., Stuckey, A.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.10.2023
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2023.09.1919